Update shared on15 Oct 2025
Fair value Increased 1.10%Analysts have slightly raised their price target for Chugai Pharmaceutical from ¥8,082 to ¥8,171, citing improved outlooks for revenue growth and profit margins.
What's in the News
- Chugai Pharmaceutical and Eli Lilly announced positive Phase 3 results from the ACHIEVE-3 trial, showing orforglipron delivered superior improvements in glycemic control and weight loss for adults with type 2 diabetes compared to oral semaglutide. (Key Developments)
- Phase 3 ATTAIN-2 trial results showed orforglipron led to significant weight loss and improvements in cardiometabolic risk factors for adults with obesity or overweight and type 2 diabetes. (Key Developments)
- The ATTAIN-1 Phase 3 trial demonstrated that orforglipron resulted in substantial weight loss for adults with obesity or overweight without diabetes, meeting all primary and secondary endpoints. (Key Developments)
- The company's board approved the construction of a new laboratory building, UKX, at the Ukima Site in Tokyo to enhance R&D and environmental initiatives as part of the TOP I 2030 strategy. (Key Developments)
Valuation Changes
- Fair Value Estimate has risen slightly from ¥8,082 to ¥8,171, reflecting a more optimistic outlook.
- Discount Rate remains unchanged at 4.72 percent, indicating a consistent risk assessment.
- Revenue Growth forecast has increased from 4.96 percent to 5.41 percent, signaling improved expectations for sales expansion.
- Net Profit Margin is projected to rise modestly from 37.43 percent to 37.84 percent.
- Future P/E ratio has declined slightly from 29.51x to 29.13x, suggesting a marginally more attractive valuation.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.